This AAF_JinLi_Readme.txt file was generated on 20221226 by Prof. Dr. Jin Li ------------------- GENERAL INFORMATION ------------------- Title of Dataset: AAF Author Information (Name, Institution, Address, Email) Principal Investigator: Prof. Dr. Jin Li, Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland, jin.li@usz.ch Alternative address: Center for Translational and Experimental Cardiology, University Hospital Zurich, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland, jin.li@uzh.ch Date of data collection (YYYYMMDD): 20200203-20221231 Geographic location of data collection: Bern and Zurich, Switzerland; Montreal, Canada; Heidelberg, Germany; Apprieu, France Information about funding sources or sponsorship that supported the collection of the data: grants from the Swiss National Science Foundation (Ambizione PZ00P3_173961 to J.L. and Eccellenza PCEFP3_203333 to J.L.). -------------------------- SHARING/ACCESS INFORMATION -------------------------- Licenses/restrictions placed on the data, or limitations of reuse: The data that support the findings of this study are available from the principal investigator and corresponding author upon reasonable request. Citation for and links to publications that cite or use the data: Maguy A, Mahendran Y, Tardif JC, Busseuil D, Li J. Autoimmune Atrial Fibrillation. Circulation 2023; DOI: 10.1161/CIRCULATIONAHA.122.062776 -------------------- DATA & FILE OVERVIEW -------------------- File list (filenames, directory structure (for zipped files) and brief description of all data files): AAF_MICROARRAY_HEAHLTHY_##_JL.csv: peptide microarray assay, raw data of fluorescence intensity (arbitrary unit), plasma sample from healthy individuals (##) (n=37) AAF_MICROARRAY_AF_##_JL.csv: peptide microarray assay, raw data of fluorescence intensity (arbitrary unit), plasma sample from patients (##) with atrial fibrillation (n=37) AAF_MICROARRAY_PREAF_##_JL.csv: peptide microarray assay, raw data of fluorescence intensity (arbitrary unit), plasma sample from patients (##), healthy at baseline, who developed atrial fibrillation on follow-up (n=14) AAF_WholeCellPatchClamp_hiPSCaCMC_AP_CTL_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, Amphotericin-perforated patch clamp, control condition, spontaneous action potential recording AAF_WholeCellPatchClamp_hiPSCaCMC_AP_CTL_CCh_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, Amphotericin-perforated patch clamp, control condition + 10 uM carbachol, spontaneous action potential recording AAF_WholeCellPatchClamp_hiPSCaCMC_AP_IgG_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, Amphotericin-perforated patch clamp, 24h purified anti-Kir3.4 IgG autoantibody from patients with atrial fibrillation, 0.5 ug/ml, spontaneous action potential recording AAF_WholeCellPatchClamp_hiPSCaCMC_AP_IgG_CCh_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, Amphotericin-perforated patch clamp, 24h purified anti-Kir3.4 IgG autoantibody from patients with atrial fibrillation, 0.5 ug/ml, + 10 uM carbachol, spontaneous action potential recording AAF_WholeCellPatchClamp_hiPSCaCMC_IKACh_CTL_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, voltage-clamp, control condition, IKACh current recording AAF_WholeCellPatchClamp_hiPSCaCMC_IKACh_CTL_CCh_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, voltage-clamp, control condition + 10 uM carbachol, IKACh current recording AAF_WholeCellPatchClamp_hiPSCaCMC_IKACh_IgG_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, voltage-clamp, 24h purified anti-Kir3.4 IgG autoantibody from patients with atrial fibrillation, 0.5 ug/ml, IKACh current recording AAF_WholeCellPatchClamp_hiPSCaCMC_IKACh_IgG_CCh_JL.csv: Human induced pluripotent stem cell-derived atrial cardiomyocytes (from Ncardia), 37°C, voltage-clamp, 24h purified anti-Kir3.4 IgG autoantibody from patients with atrial fibrillation, 0.5 ug/ml, +10 uM carbachol, IKACh current recording AAF_EPS_Mouse_CTL_##_JL.adicht: electrophysiological study in sham-immunized mice (##) AAF_EPS_Mouse_AF_##_JL.adicht: electrophysiological study in Kir3.4-immunized mice (##) Data were extracted from original sources: Patch clamp data recorded with PATCHMASTER (v2x90.5, HEKA Elektronik GmbH, Lambrecht, Germany) as .DAT files and analyzed with FITMASTER (v2x90.3, HEKA Elektronik GmbH, Lambrecht, Germany). Microarray assays performed at PEPperPRINT GmbH, Heidelberg, Germany. Electrograms were recorded with PowerLab 16/35, ADInstruments Ltd., UK. -------------------------- METHODOLOGICAL INFORMATION -------------------------- Description of methods used for collection/generation of data: Maguy A, Mahendran Y, Tardif JC, Busseuil D, Li J. Autoimmune Atrial Fibrillation. Circulation 2023; DOI: 10.1161/CIRCULATIONAHA.122.062776 Methods for processing the data: For all patch clamp data analysis the following were used: PATCHMASTER (v2x90.5, HEKA Elektronik GmbH, Lambrecht, Germany) and FITMASTER (v2x90.3, HEKA Elektronik GmbH, Lambrecht, Germany). For microarray assay analysis at PEPperPRINT GmbH (Heidelberg, Germany) the following were used: PepSlide Analyzer, R language (R version 4.0.2). Software- or Instrument-specific information needed to interpret the data, including software and hardware version numbers: For all patch clamp data analysis the following were used: PATCHMASTER (v2x90.5, HEKA Elektronik GmbH, Lambrecht, Germany) and FITMASTER (v2x90.3, HEKA Elektronik GmbH, Lambrecht, Germany). For microarray assay analysis at PEPperPRINT GmbH (Heidelberg, Germany) the following were used: PepSlide Analyzer, R language (R version 4.0.2). For electrophysiological in vivo studies the following was used: LabChart 8, ADInstruments Ltd., UK. Describe any quality-assurance procedures performed on the data: Maguy A, Mahendran Y, Tardif JC, Busseuil D, Li J. Autoimmune Atrial Fibrillation. Circulation 2023; DOI: 10.1161/CIRCULATIONAHA.122.062776 -------------------------- DATA-SPECIFIC INFORMATION -------------------------- Definition of abbreviations: AF = atrial fibrillation; AP = action potential; APD = action potential duration; hiPSCaCMC = human induced pluripotent stem cell-derived atrial cardiomyocyte; IKACh = acetylcholine-activated inwardly rectifying potassium channel current;